Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Protein Manufacturing
Overview

 

Catalog Products
Online Store
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
Complex Intelligence Technology (from BioStrand, a subsidiary of IPA)

The LENSai™ Difference

Contact Us

ENGINEERED for the AI Scientific Race

Connecting the dots for antibody discovery with a scalable framework

Overview

Revealing the right insight

To analyze increasing volumes of rich biological data and achieve results for antibody research, it is important to understand the inherent challenges of existing omics processing platforms, and their inability to connect the dots to existing databases (i.e., text, medical literature, etc.). LENSai Complex Intelligence Technology, powered by HYFT® Multi-Omics Processing (from BioStrand) technology utilizes a universal and scalable framework developed specifically to manage and analyze this pool of extremely heterogeneous omics data for antibody discovery.

HYFT Multi-Omics Processing technology within the LENSai software solves this for the field of antibody discovery.
It is at the heart of the ability to provide an agile, flexible, and scalable platform that combines all omics data – public and proprietary – into a single database, application, and user interface that enables insight across domains at the same time.

 

LENSai Technology powered by HYFT Processing enables us to:

  • sift through complex layers of information– inconceivably fast
  • create structure from unstructured data
  • extract knowledge from patterns
  • identify relevant insight
BioStrand (a subsidiary of IPA) brings meaningful data into focus for antibody discovery
Integrative:
Integrate all omics data at pangenome scale

Eliminate omics data silos. Based on HYFTs, our transversal omics language enables the unification, normalization, and standardization of all omics data. Works across species and applicable in any domain.

Efficient:
Efficiently store all omics data and metadata

The BioStrand platform indexes all sequence data and links it with relevant metadata to create a centralized, efficient, continuously available knowledgebase for your organization to leverage.

Scalable:
Analyze petabyte-scale omics data in an instant

Analyze nearly unlimited amounts of any omic data simultaneously with near instantaneous results.

Latest News:

IPA’s subsidiary BioStrand completes integration of 20 Million proprietary structural HYFTs™ and accelerates in silico drug discovery developments.

See News

Latest News:

IPA’s subsidiary BioStrand completes integration of 20 Million proprietary structural HYFTs™ and accelerates in silico drug discovery developments.

See News

Discerning intelligence for the drug discovery market

Challenges of existing artificial intelligence technologies

  • biological databases are not integrated
  • data is organized in fragments and silos
  • unable to analyze more than one database at a time
  • high sequencing expense
  • ever-increasing volume of data

The HYFT multi-omics technology solution

  • universal biological fingerprints that organize the biosphere
  • parallel analytics in multiple dimensions of text, sequence and structure – simultaneously
  • next-generation intelligence

The next evolution for CROs and the new definition of end-to-end service.

The next evolution for CROs and the new definition of end-to-end service.

Connect with IPA
Connect with us to solve your greatest biotherapeutic needs